IMPRIMIS PHARMACEUTICALS INC's ticker is IMMY and the CUSIP is 45323A201. A total of 2 filers reported holding IMPRIMIS PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $487,000 | +9.2% | 85,569 | -46.7% | 0.11% | +23.9% |
| Q3 2018 | $446,000 | +24.6% | 160,579 | -1.4% | 0.09% | +17.3% |
| Q2 2018 | $358,000 | +55.0% | 162,859 | +24.1% | 0.08% | +53.1% |
| Q1 2018 | $231,000 | -82.3% | 131,193 | -82.9% | 0.05% | -80.3% |
| Q4 2017 | $1,302,000 | +10.2% | 766,029 | +4.3% | 0.25% | +5.1% |
| Q3 2017 | $1,182,000 | -46.8% | 734,363 | +5.8% | 0.24% | -56.4% |
| Q2 2017 | $2,222,000 | -23.2% | 694,363 | 0.0% | 0.54% | -39.6% |
| Q1 2017 | $2,895,000 | +62.1% | 694,363 | -2.8% | 0.90% | +60.0% |
| Q4 2016 | $1,786,000 | -24.7% | 714,363 | +14.7% | 0.56% | -28.6% |
| Q3 2016 | $2,373,000 | +1.3% | 622,744 | 0.0% | 0.79% | -3.2% |
| Q2 2016 | $2,342,000 | -45.7% | 622,744 | 0.0% | 0.82% | -49.5% |
| Q1 2016 | $4,316,000 | 0.0% | 622,744 | 0.0% | 1.61% | +0.1% |
| Q4 2015 | $4,316,000 | – | 622,744 | – | 1.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,722,000 | $9,798,000 | 3.66% |
| Diametric Capital, LP | 252,160 | $1,453,000 | 1.12% |
| Birchview Capital, LP | 180,000 | $1,024,000 | 0.97% |
| EAM Global Investors LLC | 206,445 | $1,175,000 | 0.64% |
| EAM Investors, LLC | 301,415 | $1,715,000 | 0.47% |
| BARD ASSOCIATES INC | 51,550 | $293,000 | 0.17% |
| INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 85,569 | $487,000 | 0.11% |
| ARDSLEY ADVISORY PARTNERS LP | 75,000 | $427,000 | 0.11% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 112,859 | $642,000 | 0.04% |
| ELLINGTON MANAGEMENT GROUP LLC | 16,500 | $94,000 | 0.03% |